Endotoxin tolerance is characterized by diminished expression of inflammatory cytokines after sequential exposure to Toll-like receptor stimuli. Many mechanisms contribute to tolerance; however, chromatin remodeling appears to be the most significant regulator. The type II interferon, IFN-g, has been recognized as being able to reverse or abrogate the establishment of tolerance. Type I interferons have not been investigated previously, and they bind a distinct receptor. We found that a2-interferon was able to abrogate or diminish tolerance by endotoxin, as defined by measuring mRNA levels at recognized tolerance targets. We also found that a2-interferon treatment during tolerization was associated with increased H3K4me3 and H3K4me2 levels at promoters of tolerance targets in THP1 cells. These marks were normalized after exposure of the cells to a2-interferon. Interferon regulatory factor 1 is a transcription factor activated and induced by types I and II interferons. We found recruitment of this transcription factor paralleled tolerance and inhibition of tolerance at target genes. Therefore, there are at least 2 distinct pathways by which endotoxin tolerance may be mitigated. A type I interferon, in spite of binding to a different receptor, was just as able to inhibit tolerance as the type II interferon and also appeared to act by modifying chromatin at tolerance target genes. J. Leukoc. Biol. 98: 651-659; 2015. 
Introduction
Endotoxin tolerance is a phenomenon in which cells exposed to low concentrations of endotoxin (operationally defined as LPS in the laboratory) become much less responsive to subsequent challenges [1, 2] . This phenomenon occurs in vitro and in vivo and is relevant for several disease settings, including sepsis, cystic fibrosis, and trauma [3] [4] [5] [6] . Endotoxin tolerance is thought to have evolved to protect organisms from damage as a result of hyperinflammation [7] . Endotoxin tolerance can become pathologic, however, in settings where the body has an ongoing need to respond to pathogen threat. Various mechanisms have been described to explain the phenomenon of endotoxin tolerance. Recently, modifications to chromatin at critical target genes have been demonstrated to play an important role in endotoxin tolerance [8] [9] [10] [11] [12] [13] [14] . The histone H3K9 methyltransferase G9a is recruited to critical target genes in endotoxin tolerance and assembles a repressor complex that is responsible in part for the refractory state to subsequent stimulation [8, 10] . The repressive chromatin state blocks the ability of p65 from NF-kB to bind. Deficient recruitment of TLR adapter proteins also plays a role, as does variation in the composition of NF-kB subunits [15] [16] [17] [18] . Other phenomena appear to play an important role in endotoxin tolerance, such as changes in bioenergetics and metabolism [19] . Furthermore, microRNAs have been implicated, as in some cases mRNA levels do not correspond with protein production [20] . Nevertheless, one of the critical aspects of endotoxin tolerance revolves around the complex interplay of transcription factors and chromatin modifications.
Some of the transcription factor and signaling networks implicated in the initial response to endotoxin include NF-kB, IRF1, and STAT family members [21] . These 3 transcription factor groups are often found concomitantly on promoters [22] . In the setting of endotoxin tolerance, a different set of transcription factors appears to regulate the processes, with E26 transformationspecific family members as most important [21] . With the comparison of multiple studies across different species and cell types, the state of endotoxin tolerance is typically associated with decreased protein and message for TNF, IL-6, IL-1RA, CX3CR1, IL-10, HLA-DR, IL-8, CCL2, and IL-1 [19, 21, 23, 24] , thereby defining a common set of tolerized genes. Furthermore, there are substantial, functional consequences related to these changes in gene expression. Monocytes have increased phagocytosis and decreased antigen presentation [6, 25] .
SLE is a systemic autoimmune disease, in which type I IFNs are overproduced and contribute to the etiopathogenesis [26] [27] [28] [29] . Many potential drivers of type I IFN production have been identified. We recently identified endotoxin in the peripheral blood of SLE patients and found a gene-expression signature consistent with LPS-driven responses in peripheral blood monocytes from SLE patients [30] . In other settings, such as cystic fibrosis and sepsis, circulating endotoxin leads to endotoxin tolerance and loss of expression of genes typically induced by LPS [6] . Therefore, we hypothesized that the type I IFNs seen in SLE could overcome endotoxin tolerance in a manner similar to that of the type II IFN, IFN-g, which binds the IFN-gR and activates Jak1, Jak2, and STAT1 [31] . pSTAT1 homodimers translocate to the nucleus and bind to target genes with IFN-g-activated site motifs. Type I IFNs, in contrast, bind the IFN-aR and activate Jak1, tyrosine kinase 2, STAT1, and STAT2 [32] . The pSTATs then bind IRF9 and translocate as a complex, where they bind IFN-stimulated response elements on the genome. Therefore types I and II IFNs act via distinct receptors but share a number of functions and induce overlapping sets of genes [33] . IFN-g reversal of endotoxin tolerance, like endotoxin tolerance itself, is thought to rely on chromatin changes. Specifically, IFN-g is thought to overcome endotoxin tolerance through the recruitment of Brg1, which remodels chromatin and facilitates the loading of critical transcription factors [11] . In this study, we examined whether IFN-a could overcome endotoxin tolerance in an in vitro model. We found that IFN-a was capable of inhibiting endotoxin tolerance and was associated with marked alterations in chromatin.
MATERIALS AND METHODS

Cells, reagents, and immunofluorescence
THP1 cells are a monocytic leukemia line that has been used in endotoxin tolerance studies previously. Cells were treated with HPLC-purified LPS at 10 ng/ml (L4391; Sigma-Aldrich, St. Louis, MO, USA), IFN-a2 at 500 U/ml (P111001; VWR International, Radnor, PA, USA), or IFN-g at 50 ng/ml (285 IF; R&D Systems, Minneapolis, MN, USA) or were mock treated during the 24 h tolerization phase. Acute stimulation with LPS was performed for 90 min (Fig. 1) . Primary monocytes, purified as described previously [34] , were used to validate the effect of IFN-a. D54MG glioma cells respond to TLR stimulation and tolerate IRF1 overexpression. To make the overexpression cells, IRF1 cDNA was subcloned into pCMV6-A-puro (OriGene, Rockville, MD, USA). Both the IRF1 construct and the vector were transfected into D54MG, selected with puromycin, and used as polyclonal populations. The cells were maintained in DMEM with 10% calf serum. For immunofluorescence, THP1 cells were plated on poly-L-lysine-coated slides. Cells were fixed and stained with IRF1 (1:50, SC-74530; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or p65 (1:50, 
qRT-PCR
qRT-PCR was used to measure differences in RNA abundance after treatment. The Advantage RT-for-PCR kit (Clontech, Mountain View, CA, USA) was used to generate cDNA. Gene expression was detected by real-time PCR by use of the TaqMan 7900HT. Transcript levels were normalized to the 18S.
ChIP assays
ChIP experiments were carried out as described previously [34] [35] [36] [37] 
Statistical analyses
The experimental design was predetermined to compare L-L with AL-L. The remainder of the treatments represent controls. Therefore, there is no correction for multiple comparisons, and a t-test was used to define statistical differences. For Figs. 1 and 2 , ANOVA was applied to demonstrate the interaction of IFN-a and LPS in this model system. In each figure legend, the analysis is described and significance indicated. The n for each experiment is given in the legend.
RESULTS
SLE monocytes do not exhibit diminished expression of tolerization targets
In our RNA-seq study of SLE monocytes, we found a pattern of expression that implicated endotoxin, and high levels of endotoxin were found in SLE patient serum [30] . We did not specifically interrogate critical targets of endotoxin tolerance. Therefore, we mined our RNA-seq data specifically to define expression of genes known to be implicated in endotoxin tolerance. We selected genes defined in multiple publications as being down-regulated in the setting of endotoxin tolerance (TNF, IL-1RN, IL-1B, CCL2, CCL4, IL-6, IL-8, IL-10) and found that they were consistently up-regulated in SLE monocytes ( Table 1) . These data do not replicate the in vitro endotoxin tolerance assay but suggest that tolerance has not occurred in these cells. Type I IFNs are overproduced in SLE and contribute to the etiopathogenesis. This led us to ask whether type I IFNs might act in a manner similar to that of IFN-g Endotoxin tolerance can be reversed at the level of expression by IFN-a
We used a common two-step model, wherein low-dose LPS was used as a tolerizer (24 h) and as a stimulus (90 min; Fig. 1A ). In figure labels, letters before the hyphen indicate the treatment during the tolerization phase, and letters after the hyphen indicate the treatment during the stimulation phase (O, L, A, and G). To define first whether IFN-a can mitigate tolerance, we used the established model in primary monocytes. Cells were treated with LPS as an acute stimulus or as a tolerization strategy (Fig. 1A) . We measured TNF mRNA by use of qRT-PCR and TNF protein by use of an ELISA. LPS induced the expression of TNF (O-L bars) but when treated with sequential LPS, had much less of an effect (L-L bars). To test the effect of IFN-a, it was included with the tolerizing LPS treatment, and we noted that tolerization was inhibited. Findings for protein and RNA were comparable. We examined a series of controls to ensure that the cells behaved as expected and found that IFN-g could prime monocytes for future LPS responses (G-L) and was also capable of inhibiting the tolerance effect (GL-L compared with L-L). This is the classic reversal of endotoxin tolerance in response to IFN-g. IFN-a alone had no effect (O-A, A-O) but also primed monocytes for subsequent responses (A-L). The cell line THP1 has been used extensively in tolerance studies. We repeated these model-defining studies in THP1 cells (Fig. 2) . We compared THP1 cells tolerized by LPS, with or without IFN-a, and found that IFN-a, included at the time of LPS tolerization, restored the response to the LPS stimulation (compare the L-L and AL-L bars in Fig. 2 ), just as was the case in the primary cells. We were also able to demonstrate comparable findings for IL-1B and IL-6 in THP1 cells, although there was some variation across results for the 3 genes. These data validate our in vitro system and also clearly define the role of IFN-a in mitigating endotoxin tolerance.
Signaling molecule activation is not markedly different after IFN-a A possible explanation for the above findings is that IFN-a modifies interactions of known signaling molecules. We examined whether IFN-a could be protecting signaling molecules from endotoxin-mediated tolerance. We examined IKBA degradation, pERK, and pP38 (Fig. 3) . IKBA degraded at the 60 min time-point after LPS, as anticipated. LPS tolerance was associated with somewhat less degradation, but IFN-a did not alter that effect. pERK was observed only after acute stimulation with LPS but not after tolerance. IFN-a did not alter that finding. The pP38 was not affected by any stimulation. Thus, IFN-a did not markedly alter these central signaling pathways and did not appear to account for the ability of IFN-a to mitigate endotoxin tolerance.
Histone modifications in tolerized monocytes
Much of the recent work on endotoxin tolerance has focused on regulation via chromatin modifications [8] [9] [10] [11] [12] [13] [14] . Therefore, we performed ChIP assays to understand whether the effect of IFN-a could be mediated epigenetically. We selected proximal promoter regions from the 3 target genes for ChIP analysis. We first examined H3K4me3, a mark classically associated with gene activation [38] [39] [40] . After LPS stimulation, H3K4me3 was increased consistently across all 3 tolerance target genes (Fig. 4) . Tolerization did not reduce H3K4me3 at target genes; however, IFN-a augmented the H3K4me3 in tolerized cells. Here, our statistical analyses focused on the comparison of L-L with AL-L. Although mRNA abundance was highest in GL-L-treated cells (Fig. 2) , the H3K4me3 effect was greatest in AL-L-treated cells. Active histone marks can set a level of competence for expression, but additional proteins, such as transcription factors, can dictate the level of transcription. These data support the hypothesis that both the act of tolerance and mitigation by IFN-a are associated with changes involving histone modifications.
We also examined H3K4me2 by use of the same model (Fig. 5) . This histone mark is also associated with active genes but within promoters, tracks closely with transcription factor binding [41] . The H3K4me2 was generally lower in LPS-tolerized cells. IFN-a treatment during the tolerization phase was associated with augmented H3K4me2 levels at all 3 promoters compared with L-L treatment. Again, the effect of IFN-a during LPS tolerance appeared to be greater than that of IFN-g. Therefore, H3K4 methylation was impacted by endotoxin tolerance, and IFN-a was associated with restoration of the responsive state chromatin marks.
IRF1 and NF-kB in endotoxin tolerance
Our previous studies implicated IRF1 in the IFN signature seen in SLE. To understand whether it could have a role in endotoxin tolerance, we examined whether it could induce the expression of tolerization target genes (Fig. 6A) . All 3 targets were up-regulated in D54MG cells with IRF1 overexpression, whereas GAPDH, a common housekeeping gene, was not. We then examined the expression pattern of IRF1 in our tolerance model to determine whether its expression paralleled that of the known tolerization target genes (Fig. 6B) . IRF1 was inducible by both IFNs but was not significantly induced by LPS alone. However, IRF1 promoter chromatin modifications paralleled those of other tolerance target genes with diminished H3K4me3 and H3K4me2 in the tolerant state and restoration with IFN-a ( Fig. 6C and D) . These data suggested that expression of IRF1 is not regulated directly by LPS within the time frame of this model, but endotoxin might poise IRF1 for subsequent stimuli.
Previous studies have implicated NF-kB and IRF1 as critical transcription factors in endotoxin tolerance [10, 42] . Both NF-kB and IRF1 are activated in the cytoplasm and translocate to the nucleus to elicit their transcriptional effects. To clarify the effects, we examined nuclear translocation. We performed immunofluorescence on tolerized and stimulated cells, with and without IFN-a (Fig. 7) . L-O and L-L were both associated predominantly with nuclear IRF1 and NF-kB. This finding suggests that tolerance does not compromise activation of either protein. IFN-a and IFN-g induced IRF1 levels without changing NF-kB levels and furthermore, were associated with nuclear translocation of IRF1. When the intensity of IRF1 and NF-kB was defined by use of ImageJ, AL-L IRF1 was significantly higher than L-L IRF1 levels in the nucleus. NF-kB nuclear intensity was roughly comparable across all treatment groups. Given that total transcription of IRF1 and , IFN-a, IFN-g , and LPS were used in the tolerization phase. LPS, with or without IFN-a, was added during the stimulation phase. An anti-H3K4me2 ChIP assay was used to quantify H3K4me2 at the promoters of IL-1B, TNF, and IL-6. n = 4. Error bars represent SE. The effect of IFN-a on LPS tolerance is highlighted with the bracket, and *P , 0.05 to indicate statistical significance. translocation to the nucleus did not seem to be different between O-L and L-L, we looked at the recruitment of IRF1 to the promoter of target genes. Tolerance was associated with decreased IRF1 recruitment to the promoters, and IFN-a restored the recruitment to normal (Fig. 8A-C) . IFN-g, a known IRF1 stimulus, also led to increased IRF1 on the promoters of the tolerization target genes. This did not appear to be a result of major changes in IRF1 protein levels (Fig. 8D) , as the quantitative effects were modest. IRF1 was quantitatively induced by both IFNs but was decreased in the LPS-treated cultures, suggesting that total IRF1 levels were not responsible for target gene promoter binding. Instead, recruitment of IRF1 to target gene promoters paralleled expression and the responsive chromatin state.
DISCUSSION
In SLE, many studies have documented overproduction of inflammatory cytokines [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . Recently, more emphasis has been placed on the IFN pathway [27] [28] [29] . This pathway has been validated by multiple human studies by use of gene-expression arrays and also through the use of sensitive assays to detect type I IFNs in the plasma of patients. Yet, the older literature defining overexpression of inflammatory cytokines and the clinical response of patients to TNF inhibition suggests that the inflammatory pathway remains biologically important [44] . We identified a lupus-specific signature by RNA-seq that appeared to be induced by LPS and then found endotoxin in the plasma of SLE patients [30] . Chronic endotoxin exposure would be expected to lead to tolerance and loss of expression of inflammatory cytokines, and yet, the literature is replete with studies documenting overexpression. To resolve that apparent contradiction, we investigated the hypothesis that type I IFNs could mitigate endotoxin tolerance.
We used a common in vitro approach and found not only that IFN-a could mitigate endotoxin tolerance at the level of protein and RNA production but also that H3K4me3 and H3K4me2 peaks at target gene promoters were increased by IFN-a. These chromatin marks are usually associated with regulatory regions, such as promoters and enhancers. H3K4me3 has been demonstrated previously to be altered in regulatory regions in SLE [59] . To gain further insight into potential mechanisms, we explored the role of IRF1. This transcription factor is known to be inducible by IFNs and has been associated with a feedforward inflammatory response [42] . IRF1 recruitment to the promoters of tolerization target genes very closely paralleled expression, and when IRF1 was overexpressed, the target genes were induced. These data support a model where IFN-a participates in the modulation of the chromatin environment. The altered chromatin may control access to transcription factors, such as IRF1, similar to previous studies of endotoxin tolerance, where chromatin marks controlled access of NF-kB p65 to the promoters of inflammatory cytokines [11] . Alternatively, IRF1 could participate directly in chromatin remodeling. It has been demonstrated to interact with histone acetyltransferases [60] . Whereas relevant for endotoxin tolerance, chromatin remodeling is not the sole gatekeeper of transcription. Additional factors regulate the final level of transcript production.
This study arose from a translational study of SLE patients that demonstrated circulating endotoxin [30] . Other autoimmune diseases have been identified with a type I IFN signature [61] [62] [63] [64] [65] . It is not known if they also exhibit endotoxin translocation, but these diseases are also typically characterized by increased expression of proinflammatory cytokines. Our findings represent a new insight into the chronic inflammatory state associated with autoimmune diseases. The cytokine milieu clearly affects host responses but may color the disease state by facilitating ongoing inflammation. This study represents the first description of type I IFN effects in endotoxin tolerance; nevertheless, there are limitations to this study. This study used an in vitro cell line for ChIP assays, which may not faithfully replicate the complex interactions in vivo. Only a single type I IFN was tested, and whereas all type I IFNs use the same receptor, biologic effects do differ [66] . Therefore, it is possible that not all type I IFNs share this ability. The connection to human lupus also will require additional study. Whereas we were able to implicate IRF1 mechanistically in the expression of tolerization target genes, the protein-protein interactions that govern the relationships between IRF1 and chromatin modifications remain to be defined. IRF1 does interact with histone acetyltransferases [60] , but interactions with methyltransferases have not yet been described. Nevertheless, this study represents new information that is likely to influence thinking regarding clinical settings of prolonged endotoxin exposure. Type I IFNs are produced, not just in systemic autoimmune diseases but also in response to viral infection [67] . Systemic autoimmune diseases, such as SLE and Sjogren syndrome, have been epidemiologically associated with viral infections [68] . This study provides a potential explanation. Viral infections may foster the initial wave of type I IFNs which in combination with endotoxin exposure, resets the epigenome to facilitate the subsequent induction of inflammatory cytokines. Ultimately, a self-sustaining loop could develop. Whereas the production of IFN-g, long known to be critical for the reversal of endotoxin tolerance, is highly restricted to cytotoxic T cells and NK cells, type I IFNs are produced by a broad range of cell types. Therefore, type I IFNs may influence endotoxin responses more frequently than type II IFNs in vivo. 
